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cination program for infants was launched in Taiwan in July, 1984.
Pregnant women were screened for serum HBsAg. Infants of high-
risk mothers with positive HBeAg received HBIG within 24 h of
birth in addition to vaccines. All infants received 3 doses (at 0, 1
and 6 months of age) of recombinant HBV vaccines. All of the vac-
cines and HBIG given to the infants were paid for by the govern-
ment. HBV vaccination coverage rate is as high as 97% at present.
Following the universal hepatitis B virus (HBV) vaccination pro-
gram for infants in Taiwan 25 years ago, HBsAg sero-prevalence
declined from about 10% to 0.6% in children under 15 years old in
Taipei city during the past two decades. The sero-positive rates
for HBsAg, anti-HBs, and anti-HBc were 1.2%, 50.5%, and 3.7%,
respectively, in those born after the vaccination program (<20
years old) in 2004.
The institution of universal HBV vaccination decreases the in-
cidence of HCC in children. From 1981 to 1994, the incidence
of HCChepatocellular carcinoma in children 6 to 9 years of age
declined from 0.52/100,000 for those born between 1974 and
1984 to 0.13 for those born between 1984 and 1986 (P<0.001)
in Taiwan. Later on, we extended the follow-up to 2000, the
incidence of HCC per 100,000 children declined from 0.54 to 0.20
in those born before versus after the vaccination program.
A positive maternal HBsAg status was found in 89% of the HB-
sAg sero-positive subjects born after the vaccination program.
In spite of the success of hepatitis B immunization, childhood
HCC still failed to be completely eradicated by the universal
vaccination program. This is evidenced by the very high HBsAg
sero-positive rate in our HCC children (97%) and their mothers
(96%).
The prevalence and clinical signiﬁcance of the mutations in the
a determinant (amino acids 121–149) of HBsAg was not well elu-
cidated, particularly in the post-vaccination era. The prevalence
of a determinant mutants in HBV-DNA positive children was 7.8%
(8/103) in 1984, signiﬁcantly increased to 19.6% (10/51) in 1989,
peaked at 28.1% (9/32) in 1994, and remained at 23.1% (3/13) in
1999; it was higher in those fully vaccinated compared with those
not vaccinated (15/46 vs. 15/153; p<,0.001). However, the num-
ber of mutant infected children in each survey was stable. The
other group of subjects who are susceptible to vaccine failure is
the immune- compromized hosts.
In conclusion, universal HBV vaccination provides long-term pro-
tection up to 20 years, and a universal booster is not indicated
for the primary HBV vaccinees before adulthood. Mother-to-child
transmission is the primary reason for vaccine failure and needs
to be tackled in future vaccination programs. The emergence
of escape mutant did not impose any increased risk of chronic
infection at this moment. The development of new vaccines is
expected to overcome the vaccine failure.
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Hepatitis B virus (HBV) infection is a worldwide health problem
and the major cause of chronic hepatitis, cirrhosis as well as
hepatocellular carcinoma (HCC). HBV is an enveloped virus, con-
taining a 3.2 kb partially double-stranded DNA genome that is
replicated via an RNA intermediate using its own encoded re-
verse transcriptase (RT). The HBV RT does not have proofreading
or editing activity, therefore, together with its enormous daily
virion production, errors inevitably occur during replication in
long-term infected patients. Particular selection pressures, both
endogenous (host immune clearance) and exogenous (vaccine or
antivirals), strongly in?uence the predominant HBV quasispecies
and their biological characteristics in an infected individual at
a given time point. The mutation of HBV would bring a series
of new problems to the prevention, diagnosis and treatment of
chronic hepatitis B.
Current studies have showed that mutations in the genome
exert a substantial effect on the replication capacity of the
virus. Immune and antiviral selection pressures result in vac-
cine/immunoglobulin escape mutants and antiviral resistant
variants. Viruses encoding changes associated with antiviral
resistance often have reduced replication in vitro, but the ac-
cumulation of additional compensatory mutations helps restore
viral ﬁtness. Additionally, in our study, we found that HBV
genome variation occurred in the hepatocyte nuclear factor
(HNF) 4 and/or HNF3 binding sites may signiﬁcantly change the
capacity of viral replication.
The mechanisms determining the emergence of viral variants
in response to immune selection may be important in consider-
ing possible therapeutic interventions designed to prevent their
pathophysiological consequences. Viral variants containing two
nucleotide substitutions (A1764T and G1766A) in the proximal
nuclear hormone receptor binding site in the nucleocapsid pro-
moter are very common variants identiﬁed from patients who
have seroconversion from HBeAg to anti-HBe antibody status.
The results of our study indicate that replication of wild type
and variant viruses can be differentially regulated by nuclear
hormone receptors, and this may be important in the selection of
speciﬁc viral variants as a result of an antiviral immune response
Chronic HBV infection is a dynamic state involving interaction
between the virus, the hepatocytes and the immune cells of
the host. The role of continuing HBV replication in the hepatic
necroinﬂammatory response leading to hepatocarcinogenesis has
been showed. Several HBV mutant strains including mutations in
precore, core promoter and deletion mutation in pre-S/S genes
have been reported to be associated with the pathogenesis of
progressive liver disease, including hepatitis ﬂare, decompensa-
tion, liver cirrhosis and hepatocellular carcinoma (HCC).
The goal of therapy in patients with chronic hepatitis B is
rapid viral suppression and long-lasting maintenance of unde-
tectable levels of serum HBVDNA. Nucleoside/nucleotide ana-
logues rapidly are becoming the treatment of choice for patients
with Chronic Hepatitis B. The major draw back of this treatment
is the considerable risk of developing antiviral drug resistance as-
sociated with progressive disease, which occurs most frequently
in lamivudine-treated patients,bu talso has been shown for other
agents (eg,adefovir, telbivudine and entecavir) evaluated in
long-term studies. Location of the major antiviral drug-resistant
mutations associated with LMV,LdT,ADV,TDF,and ETV have been
identiﬁed in recent years. Antiviral therapy should be modifed as
soon as resistance is detected.
Therefore, it is necessary to monitor the occurrence and develop-
ment of HBV variations and the relationship between variability
and clinical outcome dynamically. Enhancing the biological char-
acteristics research of hepatitis B virus would help us further
understand the effect of mutations on viral replication capacity,
and better understand the roles of mutations in drug-resistance
and disease prognosis.
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It is well recognized that the transfusion of blood containing
HBsAg is associated with the development of posttransfusion
hepatitis B. This risk of acquiring an HBV infection underwent
a dramatic reduction with the advent of HBsAg screening of
blood donors in the 1970s in conjunction with the implementa-
tion of an all-volunteer donor population. Subsequent studies in
the 1980s and 1990s implicated high-titered, anti-HBc positive
blood that lacked HBsAg and anti-HBs, in the transmission of
HBV. This prompted the addition of anti-HBc screening of blood
donors in those countries where HBV is not endemic. Later, it was
discovered that the units of blood from these anti-HBc reactive,
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HBsAg-negative donors sometimes contained HBV DNA. With im-
provements in HBV DNA ampliﬁcation technology, we are now
approaching single genome detection capabilities. When coupled
with enhancements in the sensitivity and speciﬁcity of assays
for anti-HBc and HBsAg, previous misinterpretations are being
revised, and we now have a better understanding of risk.
Most experts would concur that blood collected during the early
seronegative window period of HBV (when only HBV DNA is
present) is highly infectious. This risk appears to be greater
during the expansion phase of HBV DNA than that which is seen
during the recovery phase of acute disease when anti-HBs may
complex with the virus leading to modulation of the disease pro-
cess and a reduction in the risk of transmission despite detection
of HBV DNA.
Following the uneven implementation of ultrasensitive nucleic
acid testing of blood donors in various regions of the world,
the residual risk of HBV was found to be inconstant with inci-
dence/window period rates varying from 1:350,000 in the US and
Europe to 1:50,000 in Japan and to 1:5000 or lower in Southeast
Asia and Pakistan. As interest in evaluating the residual yield of
HBV DNA positive donations in HBsAg and anti-HBc negative donor
samples (seronegative window period donations) has intensiﬁed,
some unexpected ﬁndings have emerged. For example, from Jan-
uary 2008 to January 2009, the American Red Cross (ARC) tested
3,694,858 units of blood for HBV DNA either in minipools of 16
donations (84.4%) or as individual donations (16.6%) (Stramer et
al, 2009). HBV DNA was detected in 9 donors (1:410,000) with
only one of these (11%) requiring individual testing (ID-NAT) for
detection (i.e., not detected by minipool testing). Enrollment
and follow-up data were not available for 2 of the donors. Of
the 7 remaining donors in whom data were available, 5 were
in vaccinated individuals. Four of these were anti-HBs positive
in the index donation (anti-HBs concentrations from 3-43 IU/L)
whereas one became anti-HBs positive within 45 days. Viral loads
in these index donations were low and ranged from 100-200
copies/mL (∼16-33 IU/mL). Six of the 7 donors became IgM
anti-HBc positive and only one was a ﬁrst-time donor. Of interest
was the fact that 5 of the donors were subsequently discovered
to have sexual partners who were HBV chronic carriers with HBV
DNA viral loads >108 copies/mL in the 4 samples that were
available for testing. Among the 7 genotyped donor isolates, 4
represented genomes not typically found in the US (B2, C2, D3,
F1; all from vaccinated donors) while 3 were primarily of US
origin (A2). The infected partners associated with 4 of the donors
had the same subgenotype, and full genome sequences veriﬁed
the close relationship between these isolates.
Among the 5 vaccinated donors who were followed for 119-320
days, none developed ALT levels above 19 U/L or complained of
symptoms and all became HBV DNA negative, thereby conﬁrming
the effectiveness of vaccination in preventing clinical disease.
Only 3 of the 7 HBV DNA positive donors developed detectable
HBsAg. A group in Taiwan (Wang et al, 2002) observed the devel-
opment of HBV DNA in three vaccinated children within a week
after receiving blood that resulted in an aborted subclinical
infection similar to what was seen in the ARC donors. It is note-
worthy that both unvaccinated ARC donors who were followed
for at least 228 days developed signiﬁcant ALT abnormalities (119
U/L and 640 U/L).
An important issue is whether anti-HBs in conjunction with a
low viral load in a donor is sufﬁcient to prevent transmission
of HBV to a recipient. There are several studies which suggest
that this is a rare event. Mosley et al (1995) found no HBV
transmission associated with a donor whose anti-HBs values were
at least comparable to a level of 15 IU/L regardless of anti-HBc
status. Satake et al (2007) detected no infections in 22 HBV DNA
positive components that contained anti-HBs compared to 10 in-
fections that occurred among 37 components devoid of anti-HBs
(27%). Moreover, Aach et al (1974) were unable to detect any
transmission from HBV immune donors. Dreier and coworkers
(2004) and Gerlich (2006) failed to document transmission of HBV
from donors who were HBV DNA positive at levels <260 IU/mL,
but whose blood contained signiﬁcant levels of anti-HBs (>1000
IU/L). Conversely, low levels of anti-HBs (<75 IU/L) in HBV DNA
containing blood may carry a risk of transmission leading to
acute hepatitis in a recipient (Levicnik-Stezinar et al, 2008).
Fortunately, fulminant hepatitis is virtually unheard of following
posttransfusion hepatitis B.
In summary, nucleic acid testing is capable of detecting HBV
DNA in the absence of HBsAg and anti-HBc in a limited number
of donors with a yield that approaches ∼1:410,000 donors. The
issue of transmissibility from window period donations exists at
some ﬁnite level in unvaccinated donors in which the yield is
∼1:690,000. The public health beneﬁts of HBV NAT in blood banks
remain unknown but are likely to be marginal at considerable
cost in the US and Europe, but necessary in countries where the
disease is endemic.
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The immunosuppression by chemotherapy or immunosuppressive
therapy in chronic hepatitis B virus (HBV) infection is an in-
creasing risk for reactivation of hepatitis B and may lead to
acute hepatitis, chronic hepatitis, or even fulminant hepatitis
and death. Several studies have shown a signiﬁcant beneﬁt by
antiviral therapy with lamivudine to avoid reactivation, and the
prophylaxis with antiviral agents should be superior to therapy of
reactivation.
A rational approach to avoid the reactivation hepatitis B in these
patients has been developed, including (a) the evaluation of
HBV markers and liver condition in all patients before starting
immunosuppressive therapies; (b) the vaccination to patients
without detection of HBsAg or without sufﬁcient anti-HBs-titer;
(c) the treatment with antiviral agents of chronic hepatitis B
patients; (d) the prophylaxis use of antiviral agents such as
lamivudine in all HBsAg positive carriers; (d) the biochemical,
HBsAg and HBV DNA monitoring in subjects with HBsAg negative
and anti-HBc positive, or in subjects with markers of previous
contact with HBV; (e) the prophylaxis use of antiviral agents
before intense immunosuppression such as bone marrow trans-
plantation if anti-HBc positive, independent from HBsAg result.
Lamivudine has been approved to be effective and safe in
the management of immunosuppressive patients, other nucleo-
side analogues (telbivudine, entecavir) or nucleotide analogues
(adefovir dipivoxil, tenofovir) are potential candidates in this
situation, but larger experiences are yet missing.
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Resistance in Mycobacterium tuberculosis arises from man-made
selection of genetic mutants that result from spontaneous chro-
mosomal alterations. Thus, drug-resistant tuberculosis (TB) is
generally due to inappropriate treatment regimen, poor drug
quality, erratic drug supply and poor patient adherence to treat-
ment, reﬂecting failure in the implementation of an effective
TB control programme. Multidrug-resistant TB (MDR-TB) usually
denotes bacillary resistance to at least isoniazid and rifampicin
in vitro. Directly observed treatment, short-course (DOTS) is a
cost-effective strategy for TB control. Proper implementation of
the DOTS strategy should achieve a high cure rate for disease
